Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.

Toshiaki IwaseKenichi HaranoHiroko MasudaKumiko KidaKenneth R HessYing WangLuc DirixSteven J Van LaereAnthony LucciSavitri KrishnamurthyWendy A WoodwardRachel M LaymanFrançois BertucciNaoto Tada Ueno

Published in: BMC cancer (2020)

Higher ER expression was significantly associated with improved survival in both HR+/HER2- IBC and HR+/HER2- stage III non-IBC patients. HR+/HER2- IBC had several activated pathways with MYC upregulation, and the genetic alteration was associated with poor survival outcome. The results indicate that MYC may be a key gene for understanding the biology of HR+/HER2- IBC.

Keyphrases

poor prognosis
genome wide
end stage renal disease
copy number
genome wide identification
chronic kidney disease
transcription factor
oxidative stress
long non coding rna
gene expression
binding protein
prognostic factors
peritoneal dialysis
high resolution
free survival
dna methylation